<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782509</url>
  </required_header>
  <id_info>
    <org_study_id>1222.12</org_study_id>
    <secondary_id>2008-003704-67</secondary_id>
    <nct_id>NCT00782509</nct_id>
  </id_info>
  <brief_title>12 / 48 wk Pivotal PFT vs PBO in COPD II</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This primary objective of this study is to compare two doses of BI 1744 CL inhalation
      solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic
      obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 Response at Day 85 (12 Weeks)</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and -1h and -10 min, 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h relative to dose at Day 85 (12 weeks)</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response At Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -1h, -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 2 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed a -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 6 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 18 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 18 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 24 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 32 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 32 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 40 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 40 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 48 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response At Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response At Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 2 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 6 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 12 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 12 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 18 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 18 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 24 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 32 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 32 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 40 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 40 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 48 Weeks</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Response At Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours aftertreatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Response After 6 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Response After 12 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Response After 24 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak (0-3h) Response After 48 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and -1h and -10 min, 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h relative to dose at Day 85 (12 weeks)</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FVC AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEF)</measure>
    <time_frame>immediately upon arising (before drug administration) from Screening to week 48</time_frame>
    <description>Weekly mean pre-dose morning peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Evening Peak Expiratory Flow Rate (PEF)</measure>
    <time_frame>at bedtime from Screening to week 48</time_frame>
    <description>Weekly mean evening peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean of Daily Daytime Rescue Use</measure>
    <time_frame>Week 48</time_frame>
    <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each day during week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean of Daily Nighttime Rescue Use</measure>
    <time_frame>Week 48</time_frame>
    <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each night during week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean of Daily (24h) Rescue Use</measure>
    <time_frame>Week 48</time_frame>
    <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each 24 hour period during week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating at Week 6</measure>
    <time_frame>Week 6 visit</time_frame>
    <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating at Week 12</measure>
    <time_frame>Week 12 visit</time_frame>
    <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating at Week 24</measure>
    <time_frame>Week 24 visit</time_frame>
    <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating at Week 48</measure>
    <time_frame>Week 48 visit</time_frame>
    <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank.
The measured values presented are actually the First Quartile and 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Qualifying events of COPD were specifically pre-defined in the protocol.Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations</measure>
    <time_frame>Baseline to end of study at week 48 visit</time_frame>
    <description>Mean number of COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations Requiring Hospitalization</measure>
    <time_frame>Baseline to end of study at week 48 visit</time_frame>
    <description>Mean number of COPD exacerbations requiring hospitalization per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</measure>
    <time_frame>Baseline to end of study at 48 weeks.</time_frame>
    <description>Mean number of moderate COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Safety Parameters Related to Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Occurence of bronchoconstriction, cardiac disorders and investigations related to treatment. Bronchoconstriction is defined as any of the following events: Drop in trough FEV1 &gt;= 15%, Rescue medication use within 30 min of inhaling randomized treatment on a clinic test day or Cough, wheeze, or dyspnoea AE within 30 min of inhaling randomized treatment on a clinic test day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Potassium</measure>
    <time_frame>Day 1 and at 12, 24 and 48 weeks</time_frame>
    <description>Laboratory testing: Average change from baseline of potassium measured. The laboratory tests at Day 1 were considered the baseline measurements.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">644</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Olodaterol (BI1744) Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744)</intervention_name>
    <description>Comparison of low and high doses on efficacy and safety in COPD patients</description>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744)</intervention_name>
    <description>Comparison of low and high doses on efficacy and safety in COPD patients</description>
    <arm_group_label>Olodaterol (BI1744) Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  All patients must have a diagnosis of chronic obstructive pulmonary disease

          -  Male or female patients, 40 years of age or older Patients must be current or
             ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1
             &lt;80% predicted and post-bronchodilator FEV1/FVC &lt;70%

        Exclusion criteria:

          -  Patients with a significant disease other than COPD

          -  Patients with a history of asthma

          -  Patients with any of the following conditions:

        a history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or
        life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the
        past year. known active tuberculosis a malignancy for which patient has undergone
        resection, radiation therapy or chemotherapy within last five years (patients with treated
        basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a
        history of cystic fibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.12.1227 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1218 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1226 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1214 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1224 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1222 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1220 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1229 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1219 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1233 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1228 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1213 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1223 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1217 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnatti</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1230 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1216 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1221 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1212 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1225 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1232 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1298 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1296 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1297 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1299 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1300 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1269 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1270 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1271 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1268 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1266 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1272 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1267 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1289 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1290 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1288 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1287 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.12.1286 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Germany</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>644 patients were randomised into the study, however two of the patients were not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="216"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons not stated above</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B2">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B3">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="216"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="217"/>
            <count group_id="B4" value="642"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="8.3"/>
                    <measurement group_id="B2" value="64.7" spread="8.1"/>
                    <measurement group_id="B3" value="65.4" spread="9.7"/>
                    <measurement group_id="B4" value="64.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tiotropium (Tio) Use Stratum</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-tiotropium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiotropium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks)</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before Day 85 (12 weeks) for either co-primary efficacy variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks)</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all randomized patients who received at least one dose of treatment and had both baseline data and at least one post-baseline measurement at or before Day 85 (12 weeks) for either co-primary efficacy variable.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.013"/>
                    <measurement group_id="O2" value="0.159" spread="0.013"/>
                    <measurement group_id="O3" value="0.152" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.151</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response at Day 85 (12 Weeks)</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Day 85 (12 Weeks)</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.014"/>
                    <measurement group_id="O2" value="0.044" spread="0.014"/>
                    <measurement group_id="O3" value="0.045" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0116</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.012</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and -1h and -10 min, 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h relative to dose at Day 85 (12 weeks)</time_frame>
        <population>Patients in FAS with spirometry data after 3 hours at Visit 5 (12-hour pulmonary function test set)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>Patients in FAS with spirometry data after 3 hours at Visit 5 (12-hour pulmonary function test set)</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.021"/>
                    <measurement group_id="O2" value="0.120" spread="0.020"/>
                    <measurement group_id="O3" value="0.100" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment, tiotropium stratum and baseline as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, tiotropium stratum and baseline as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response At Day 1</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response At Day 1</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.013"/>
                    <measurement group_id="O2" value="0.189" spread="0.013"/>
                    <measurement group_id="O3" value="0.196" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.164</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.131</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.171</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.013"/>
                    <measurement group_id="O2" value="0.188" spread="0.013"/>
                    <measurement group_id="O3" value="0.177" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -1h, -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.013"/>
                    <measurement group_id="O2" value="0.180" spread="0.013"/>
                    <measurement group_id="O3" value="0.171" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.135</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.013"/>
                    <measurement group_id="O2" value="0.155" spread="0.013"/>
                    <measurement group_id="O3" value="0.126" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.165</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.131</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.030" spread="0.013"/>
                    <measurement group_id="O2" value="0.132" spread="0.013"/>
                    <measurement group_id="O3" value="0.128" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed a -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 2 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed a -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.014"/>
                    <measurement group_id="O2" value="0.066" spread="0.014"/>
                    <measurement group_id="O3" value="0.078" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.014"/>
                    <measurement group_id="O2" value="0.071" spread="0.014"/>
                    <measurement group_id="O3" value="0.082" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 18 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 18 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 18 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.014"/>
                    <measurement group_id="O2" value="0.062" spread="0.014"/>
                    <measurement group_id="O3" value="0.037" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.014"/>
                    <measurement group_id="O2" value="0.033" spread="0.014"/>
                    <measurement group_id="O3" value="0.022" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 32 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 32 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 32 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.014"/>
                    <measurement group_id="O2" value="0.029" spread="0.014"/>
                    <measurement group_id="O3" value="-0.002" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1614</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.011</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 40 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 40 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 40 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.014"/>
                    <measurement group_id="O2" value="0.033" spread="0.014"/>
                    <measurement group_id="O3" value="0.043" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.057" spread="0.014"/>
                    <measurement group_id="O2" value="0.011" spread="0.014"/>
                    <measurement group_id="O3" value="0.014" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response At Day 1</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response At Day 1</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.014"/>
                    <measurement group_id="O2" value="0.267" spread="0.014"/>
                    <measurement group_id="O3" value="0.276" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.177</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.142</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="0.014"/>
                    <measurement group_id="O2" value="0.259" spread="0.014"/>
                    <measurement group_id="O3" value="0.251" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.014"/>
                    <measurement group_id="O2" value="0.252" spread="0.014"/>
                    <measurement group_id="O3" value="0.246" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.202</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" spread="0.014"/>
                    <measurement group_id="O2" value="0.232" spread="0.014"/>
                    <measurement group_id="O3" value="0.217" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="0.014"/>
                    <measurement group_id="O2" value="0.226" spread="0.014"/>
                    <measurement group_id="O3" value="0.197" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.164</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.128</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.135</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" spread="0.014"/>
                    <measurement group_id="O2" value="0.197" spread="0.014"/>
                    <measurement group_id="O3" value="0.198" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.120</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response At Day 1</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response At Day 1</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.026"/>
                    <measurement group_id="O2" value="0.383" spread="0.026"/>
                    <measurement group_id="O3" value="0.384" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.331</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.263</ci_lower_limit>
            <ci_upper_limit>0.399</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.333</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.265</ci_lower_limit>
            <ci_upper_limit>0.400</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.026"/>
                    <measurement group_id="O2" value="0.338" spread="0.026"/>
                    <measurement group_id="O3" value="0.323" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.174</ci_lower_limit>
            <ci_upper_limit>0.310</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.226</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.294</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.026"/>
                    <measurement group_id="O2" value="0.312" spread="0.027"/>
                    <measurement group_id="O3" value="0.294" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.263</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.195</ci_lower_limit>
            <ci_upper_limit>0.332</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.246</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.315</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="0.026"/>
                    <measurement group_id="O2" value="0.284" spread="0.027"/>
                    <measurement group_id="O3" value="0.291" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.239</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.308</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.245</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.176</ci_lower_limit>
            <ci_upper_limit>0.314</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="0.027"/>
                    <measurement group_id="O2" value="0.303" spread="0.027"/>
                    <measurement group_id="O3" value="0.281" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.241</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.171</ci_lower_limit>
            <ci_upper_limit>0.311</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.219</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.289</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.027"/>
                    <measurement group_id="O2" value="0.271" spread="0.027"/>
                    <measurement group_id="O3" value="0.271" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.217</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.147</ci_lower_limit>
            <ci_upper_limit>0.288</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.218</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.148</ci_lower_limit>
            <ci_upper_limit>0.288</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 2 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.028"/>
                    <measurement group_id="O2" value="0.113" spread="0.028"/>
                    <measurement group_id="O3" value="0.141" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1040</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0172</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.028"/>
                    <measurement group_id="O2" value="0.122" spread="0.028"/>
                    <measurement group_id="O3" value="0.147" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0106</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.043" spread="0.028"/>
                    <measurement group_id="O2" value="0.075" spread="0.028"/>
                    <measurement group_id="O3" value="0.091" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3821</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1917</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 18 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 18 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 18 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.028"/>
                    <measurement group_id="O2" value="0.114" spread="0.028"/>
                    <measurement group_id="O3" value="0.098" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1808</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3700</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.028"/>
                    <measurement group_id="O2" value="0.066" spread="0.028"/>
                    <measurement group_id="O3" value="0.091" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2312</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0596</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 32 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 32 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 32 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.028"/>
                    <measurement group_id="O2" value="0.099" spread="0.028"/>
                    <measurement group_id="O3" value="0.058" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3110</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.111</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9426</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 40 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 40 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 40 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="0.028"/>
                    <measurement group_id="O2" value="0.104" spread="0.028"/>
                    <measurement group_id="O3" value="0.131" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2680</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0662</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.028"/>
                    <measurement group_id="O2" value="0.038" spread="0.028"/>
                    <measurement group_id="O3" value="0.054" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2249</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0994</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Response At Day 1</title>
        <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours aftertreatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Response At Day 1</title>
          <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours aftertreatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" spread="0.027"/>
                    <measurement group_id="O2" value="0.534" spread="0.028"/>
                    <measurement group_id="O3" value="0.535" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.332</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.261</ci_lower_limit>
            <ci_upper_limit>0.403</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.333</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.263</ci_lower_limit>
            <ci_upper_limit>0.403</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.254" spread="0.027"/>
                    <measurement group_id="O2" value="0.479" spread="0.028"/>
                    <measurement group_id="O3" value="0.464" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.225</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.153</ci_lower_limit>
            <ci_upper_limit>0.296</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Response After 6 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Response After 6 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.183" spread="0.028"/>
                    <measurement group_id="O2" value="0.451" spread="0.028"/>
                    <measurement group_id="O3" value="0.434" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.268</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.196</ci_lower_limit>
            <ci_upper_limit>0.340</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.251</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>0.323</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Response After 12 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Response After 12 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.213" spread="0.028"/>
                    <measurement group_id="O2" value="0.439" spread="0.028"/>
                    <measurement group_id="O3" value="0.422" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.226</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.298</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Response After 24 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Response After 24 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.223" spread="0.028"/>
                    <measurement group_id="O2" value="0.449" spread="0.028"/>
                    <measurement group_id="O3" value="0.429" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.226</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.153</ci_lower_limit>
            <ci_upper_limit>0.299</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.206</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.279</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak (0-3h) Response After 48 Weeks</title>
        <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak (0-3h) Response After 48 Weeks</title>
          <description>Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.208" spread="0.028"/>
                    <measurement group_id="O2" value="0.415" spread="0.028"/>
                    <measurement group_id="O3" value="0.419" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.207</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.280</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model with trt,tio stratum,visit,trt-by-visit as fixed effects,baseline, baseline-by-visit as fixed covariates, patient as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.285</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FVC AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and -1h and -10 min, 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h relative to dose at Day 85 (12 weeks)</time_frame>
        <population>Patients in FAS with spirometry data after 3 hours at Visit 5 (12-hour pulmonary function test set)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FVC AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>Patients in FAS with spirometry data after 3 hours at Visit 5 (12-hour pulmonary function test set)</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.036"/>
                    <measurement group_id="O2" value="0.199" spread="0.035"/>
                    <measurement group_id="O3" value="0.212" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment, tiotropium stratum and baseline as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment, tiotropium stratum and baseline as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEF)</title>
        <description>Weekly mean pre-dose morning peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.</description>
        <time_frame>immediately upon arising (before drug administration) from Screening to week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEF)</title>
          <description>Weekly mean pre-dose morning peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.939" spread="3.800"/>
                    <measurement group_id="O2" value="196.300" spread="3.868"/>
                    <measurement group_id="O3" value="203.873" spread="3.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.360</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.959</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.622</ci_lower_limit>
            <ci_upper_limit>23.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.934</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.894</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.323</ci_lower_limit>
            <ci_upper_limit>30.545</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Evening Peak Expiratory Flow Rate (PEF)</title>
        <description>Weekly mean evening peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.</description>
        <time_frame>at bedtime from Screening to week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Evening Peak Expiratory Flow Rate (PEF)</title>
          <description>Weekly mean evening peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.502" spread="3.987"/>
                    <measurement group_id="O2" value="207.958" spread="4.065"/>
                    <measurement group_id="O3" value="216.155" spread="3.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0169</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.456</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.242</ci_lower_limit>
            <ci_upper_limit>22.670</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.653</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.574</ci_lower_limit>
            <ci_upper_limit>30.731</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean of Daily Daytime Rescue Use</title>
        <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each day during week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean of Daily Daytime Rescue Use</title>
          <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each day during week 48.</description>
          <population>FAS</population>
          <units>Number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.363" spread="0.097"/>
                    <measurement group_id="O2" value="0.947" spread="0.099"/>
                    <measurement group_id="O3" value="0.850" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.416</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.127</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.665</ci_lower_limit>
            <ci_upper_limit>-0.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.513</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.125</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.760</ci_lower_limit>
            <ci_upper_limit>-0.267</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean of Daily Nighttime Rescue Use</title>
        <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each night during week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean of Daily Nighttime Rescue Use</title>
          <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each night during week 48.</description>
          <population>FAS</population>
          <units>Number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.072" spread="0.121"/>
                    <measurement group_id="O2" value="1.652" spread="0.123"/>
                    <measurement group_id="O3" value="1.312" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.420</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.157</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.729</ci_lower_limit>
            <ci_upper_limit>-0.111</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.760</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.155</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.065</ci_lower_limit>
            <ci_upper_limit>-0.456</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean of Daily (24h) Rescue Use</title>
        <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each 24 hour period during week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean of Daily (24h) Rescue Use</title>
          <description>The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each 24 hour period during week 48.</description>
          <population>FAS</population>
          <units>Number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.436" spread="0.193"/>
                    <measurement group_id="O2" value="2.599" spread="0.197"/>
                    <measurement group_id="O3" value="2.158" spread="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.837</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.252</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.333</ci_lower_limit>
            <ci_upper_limit>-0.342</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>non−MMRM ANCOVA models with treatment, tiotropium strata and baseline as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.278</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.249</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.767</ci_lower_limit>
            <ci_upper_limit>-0.789</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating at Week 6</title>
        <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
        <time_frame>Week 6 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating at Week 6</title>
          <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
          <population>FAS</population>
          <units>Point on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.1"/>
                    <measurement group_id="O2" value="3.0" spread="0.1"/>
                    <measurement group_id="O3" value="2.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0122</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum, visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum, visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating at Week 12</title>
        <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
        <time_frame>Week 12 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating at Week 12</title>
          <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
          <population>FAS</population>
          <units>Point on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.1"/>
                    <measurement group_id="O2" value="2.9" spread="0.1"/>
                    <measurement group_id="O3" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum, visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0169</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum, visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating at Week 24</title>
        <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
        <time_frame>Week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating at Week 24</title>
          <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
          <population>FAS</population>
          <units>Point on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.1"/>
                    <measurement group_id="O2" value="3.0" spread="0.1"/>
                    <measurement group_id="O3" value="2.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0180</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum, visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum, visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Rating at Week 48</title>
        <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
        <time_frame>Week 48 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Rating at Week 48</title>
          <description>Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.</description>
          <population>FAS</population>
          <units>Point on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.1"/>
                    <measurement group_id="O2" value="3.1" spread="0.1"/>
                    <measurement group_id="O3" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1313</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum,visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0089</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, tiotropium stratum visit and treatment-by-visit interaction as fixed effects, patient as random.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank.
The measured values presented are actually the First Quartile and 95% confidence interval.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - tiotropium use stratum</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Non-tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - non-tiotropium use stratum.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd (Tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg qd (Non-tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd (Tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O6">
            <title>Olo 10 mcg qd(Non-tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank.
The measured values presented are actually the First Quartile and 95% confidence interval.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.0" lower_limit="98.0">N/A indicates this statistic was not available due to the low number N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O2" value="259.0" lower_limit="169.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O3" value="225.0" lower_limit="41.0" upper_limit="336.0"/>
                    <measurement group_id="O4" value="315.0" lower_limit="196.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O5" value="219.0" lower_limit="74.0" upper_limit="327.0"/>
                    <measurement group_id="O6" value="216.0" lower_limit="170.0" upper_limit="307.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9853</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.993</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.187</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.687</ci_lower_limit>
            <ci_upper_limit>1.436</ci_upper_limit>
            <estimate_desc>Comparison of Olo 5 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2344</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.241</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.222</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.873</ci_lower_limit>
            <ci_upper_limit>1.763</ci_upper_limit>
            <estimate_desc>Comparison of Olo 10 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - tiotropium use stratum</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Non-tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - non-tiotropium use stratum.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd (Tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg qd (Non-tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd (Tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O6">
            <title>Olo 10 mcg qd(Non-tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O2" value="NA">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="305.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O4" value="NA">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O5" value="NA">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O6" value="NA">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9035</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.438</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.463</ci_lower_limit>
            <ci_upper_limit>2.380</ci_upper_limit>
            <estimate_desc>Comparison of Olo 5 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9304</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.958</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.408</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.415</ci_lower_limit>
            <ci_upper_limit>2.209</ci_upper_limit>
            <estimate_desc>Comparison of Olo 10 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Qualifying events of COPD were specifically pre-defined in the protocol.Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval..</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - tiotropium use stratum</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Non-tiotropium)</title>
            <description>Matching Placebo delivered by the Respimat Inhaler - non-tiotropium use stratum.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd (Tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg qd (Non-tiotropium)</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd (Tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - tiotropium stratum</description>
          </group>
          <group group_id="O6">
            <title>Olo 10 mcg qd(Non-tiotropium)</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler - non-tiotropium stratum</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Qualifying events of COPD were specifically pre-defined in the protocol.Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval..</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="211.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O2" value="362.0" lower_limit="226.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="65.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="235.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O5" value="225.0" lower_limit="111.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                    <measurement group_id="O6" value="308.0" lower_limit="208.0">N/A indicates this statistic was not available due to the low number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6690</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.090</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.233</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.717</ci_lower_limit>
            <ci_upper_limit>1.657</ci_upper_limit>
            <estimate_desc>Comparison of Olo 5 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1437</p_value>
            <method>Log Rank</method>
            <method_desc>Model included a stratification factor for tiotropium use stratum and a covariate for treatment group</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.344</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.273</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.902</ci_lower_limit>
            <ci_upper_limit>2.002</ci_upper_limit>
            <estimate_desc>Comparison of Olo 10 mcg qd to placebo across stratum</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations</title>
        <description>Mean number of COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.</description>
        <time_frame>Baseline to end of study at week 48 visit</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations</title>
          <description>Mean number of COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>COPD exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4590" spread="0.0687"/>
                    <measurement group_id="O2" value="0.5453" spread="0.0765"/>
                    <measurement group_id="O3" value="0.5885" spread="0.0799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3637</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.1880</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2251</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8188</ci_lower_limit>
            <ci_upper_limit>1.7234</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1853</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.2822</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2403</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8874</ci_lower_limit>
            <ci_upper_limit>1.8527</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations Requiring Hospitalization</title>
        <description>Mean number of COPD exacerbations requiring hospitalization per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.</description>
        <time_frame>Baseline to end of study at week 48 visit</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Requiring Hospitalization</title>
          <description>Mean number of COPD exacerbations requiring hospitalization per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>COPD exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0786" spread="0.0273"/>
                    <measurement group_id="O2" value="0.0811" spread="0.0268"/>
                    <measurement group_id="O3" value="0.0886" spread="0.0287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9455</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.0314</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4664</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4244</ci_lower_limit>
            <ci_upper_limit>2.5063</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7883</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.1273</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4696</ci_lower_limit>
            <ci_upper_limit>2.7064</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</title>
        <description>Mean number of moderate COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.</description>
        <time_frame>Baseline to end of study at 48 weeks.</time_frame>
        <population>Treated set- all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</title>
          <description>Mean number of moderate COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.</description>
          <population>Treated set- all patients who received at least one dose of study medication</population>
          <units>COPD exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3375" spread="0.0587"/>
                    <measurement group_id="O2" value="0.4335" spread="0.0699"/>
                    <measurement group_id="O3" value="0.4513" spread="0.0701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2514</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.2846</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2803</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8370</ci_lower_limit>
            <ci_upper_limit>1.9717</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1807</p_value>
            <method>Negative binomial regression</method>
            <method_desc>Regression of treatment effect using tiotropium strata as a covariate, a log link function and log(exposure) as offset.</method_desc>
            <param_type>Incidence rate ratio</param_type>
            <param_value>1.3373</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2901</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8735</ci_lower_limit>
            <ci_upper_limit>2.0474</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Safety Parameters Related to Treatment</title>
        <description>Occurence of bronchoconstriction, cardiac disorders and investigations related to treatment. Bronchoconstriction is defined as any of the following events: Drop in trough FEV1 &gt;= 15%, Rescue medication use within 30 min of inhaling randomized treatment on a clinic test day or Cough, wheeze, or dyspnoea AE within 30 min of inhaling randomized treatment on a clinic test day.</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Safety Parameters Related to Treatment</title>
          <description>Occurence of bronchoconstriction, cardiac disorders and investigations related to treatment. Bronchoconstriction is defined as any of the following events: Drop in trough FEV1 &gt;= 15%, Rescue medication use within 30 min of inhaling randomized treatment on a clinic test day or Cough, wheeze, or dyspnoea AE within 30 min of inhaling randomized treatment on a clinic test day.</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronchoconstriction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram QT prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supraventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular block first degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular block second degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bundle branch block left</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Potassium</title>
        <description>Laboratory testing: Average change from baseline of potassium measured. The laboratory tests at Day 1 were considered the baseline measurements.</description>
        <time_frame>Day 1 and at 12, 24 and 48 weeks</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Potassium</title>
          <description>Laboratory testing: Average change from baseline of potassium measured. The laboratory tests at Day 1 were considered the baseline measurements.</description>
          <population>Treated set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.4"/>
                    <measurement group_id="O2" value="-0.0" spread="0.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olo 5 mcg</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 10 mcg</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

